Eculizumab Drug Asset Due Diligence Report 2026

This Eculizumab Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

Registered trials

181

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Eculizumab can convert its Monoclonal antibody profile and C5 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Eculizumab (query alias: Eculizumab)
Modality / target	Monoclonal antibody; C5; C5 inhibitors
Highest global status	Approved
Originator	Alexion Pharmaceuticals, Inc.
Active developers	Alexion Pharmaceuticals, Inc., AstraZeneca Global R&D (China) Co., Ltd., Alexion Europe SAS

The MCP disease footprint includes AQP4-IgG positive Neuromyelitis optica spectrum disorder, Atypical Hemolytic Uremic Syndrome, Myasthenia Gravis. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
ChiCTR2600122544	Phase 4	Pending	20	24-week Complete Renal Remission Rate (CRR)
ChiCTR2600122042	Phase 4	Not yet recruiting	20	Complete Response Rate(defined as absence of clinical manifestations of vasculitis and glomerulonephritis, with BVAS=0 and stable or improved eGFR
NCT07420296	Phase 3	Recruiting	198	Best corrected visual acuity

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

ASSESSMENT OF THE USE OF BIOLOGIC DRUGS IN THE TREATMENT OF PRIMARY ANTIPHOSPHOLIPID ANTIBODY SYNDROME

Not Applicable; n=100; evaluation: Positive. Reported fields: clinical improvement(complement-mediated APS presentations) = 60.0 % ; -

DANICOPAN ADD-ON THERAPY IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: UK EXPERIENCE

Not Applicable; n=34; evaluation: Positive. Reported fields: ARC(12-month) = 162.2 x10^9/L

3-YEAR EFFICACY AND SAFETY OF CROVALIMAB IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) NAIVE TO COMPLEMENT INHIBITORS: LONG-TERM DATA FROM THE PHASE III COMMODORE 2 TRIAL

Phase 3; n=204; evaluation: Positive. Reported fields: Adverse Event: Transient immune complex reactions (TICRs) = 18% of Arm B switch pts (12/68) during the extension period ; Adverse Event: Transient immune complex reactions (TICRs) = 18% of Arm B switch pts (12/68) during the extension period ; Adverse Event: Transient immune complex reactions (TICRs) = 18% of Arm B switch pts (12/68) during the extension period

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Eculizumab addresses AQP4-IgG positive Neuromyelitis optica spectrum disorder, Atypical Hemolytic Uremic Syndrome, Myasthenia Gravis. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Monoclonal antibody—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 1 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2020-12-12	AstraZeneca completed the acquisition of Alexion Pharmaceuticals, Inc.	Approved	US$39,000.0M stated total

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Improved eculizumab precision dosing”. The milestone feed surfaced a patent-application signal described as “Dosage and administration of Anti-c5 antibodies for preventing or minimizing cardiac surgery associated acute kidney injury (CSA-AKI) and/or subsequent major adverse kidney events (MAKE) in patients with chronic kidney disease”. The milestone feed surfaced a patent-application signal described as “Supplemental dosage and administration of Anti-c5 antibodies for treating hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA)”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Class crowding and differentiation versus other PD-(L)1/VEGF agents
Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
Biomarker strategy, indication selection, and head-to-head endpoint execution

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO